X

Drug Profile

Research programme: kamuvudines - Inflammasome Therapeutics

Latest Information Update: 02 May 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Inflammasome Therapeutics
Class Eye disorder therapies
Mechanism of Action Inflammasome inhibitors; NLRP3 protein inhibitors; Nucleoside reverse transcriptase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Age-related macular degeneration; Type 2 diabetes mellitus

Most Recent Events

29 Apr 2024 Updated pharmacodynamics data from a preclinical trial Age-related macular degeneration released by Inflammasome Therapeutics
06 Dec 2021 Inflammasome Therapeutics plans a clinical trial in 2022
05 Feb 2021 Inflammasome Therapeutics has pending patents for kamuvudines in Australia, Europe, Canada

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com